DelveInsight’s “Alopecia Areata - Pipeline Insight, 2023,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Alopecia Areata pipeline landscape.
Key Takeaways from the Alopecia Areata Pipeline Report
- Over 18+ companies and 20+ pipeline drugs Alopecia Areata pipeline therapies are in various stages of development, and their anticipated acceptance in the Alopecia Areata market would significantly increase market revenue.
- Leading Alopecia Areata companies developing novel drug candidates to improve the Concert Pharmaceutical, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others
- Promising Alopecia Areata pipeline therapies in various stages of development include Deuruxolitinib, EQ101, MAX 40070, and others.
Alopecia Areata Overview
Alopecia areata (AA) is a form of alopecia that impacts hair follicles, nails, and rarely, the retinal pigment epithelium. It typically presents with round patches and is a type of non-scarring hair loss. A significant feature of the hair follicle is its relative immune privilege, this mainly established by suppression of surface molecules required for presenting auto antigens to CD8+ T lymphocytes (i.e., MHC class I) and by the generation of an inhibitory local signaling environment. The breakdown of the immune privilege of the hair follicle has been thought to be a significant driver of AA.
Alopecia areata is a disorder of hair follicle-cycling, where inflammatory cells attack the hair follicle matrix epithelium that is undergoing early cortical differentiation (anagen hair follicles), which are then precipitately induced into the catagen phase. However, since no destruction of hair-follicle stem cells occurs, the hair follicle retains its capacity to regenerate and continue cycling. Thereby, follicles re-enter the anagen phase normally but do not develop beyond the anagen III/IV phase.
Discover more about the emerging Alopecia Areata drugs @ Alopecia Areata Treatment Drugs
Alopecia Areata Pipeline Therapies and Key Companies
- Deuruxolitinib: Concert Pharmaceuticals
- EQ101: Equillium
- MAX 40070: Maxinovel Pharmaceuticals
And many others
Alopecia Areata Pipeline Therapeutics Assessment
DelveInsight’s Report covers around 20+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Scope of the Alopecia Areata Pipeline Report
- Coverage: Global
- Key Alopecia Areata Companies: Concert Pharmaceutical, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited, and others
- Key Alopecia Areata Pipeline Therapies: Deuruxolitinib, EQ101, MAX 40070, and others.
- Find out more about the Alopecia Areata treatment options in development @ Alopecia Areata Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
